Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial
Hyperuricaemia and gout are common in chronic kidney disease (CKD). We aimed to assess the effects of sodium-glucose co-transporter-2 (SGLT2) inhibition on uric acid (urate) and gout in patients with CKD.The EMPA-KIDNEY trial randomised 6609 patients with CKD to receive either empagliflozin 10 mg da...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
April 2025
|
| In: |
Nephrology, dialysis, transplantation
Year: 2025, Volume: 40, Issue: 4, Pages: 720-730 |
| ISSN: | 1460-2385 |
| DOI: | 10.1093/ndt/gfae203 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1093/ndt/gfae203 |
| Author Notes: | Kaitlin J. Mayne, Rebecca J. Sardell, Natalie Staplin, Parminder K. Judge, Doreen Zhu, Emily Sammons, David Z.I. Cherney, Jennifer B. Green, Adeera Levin, Roberto Pontremoli, Sibylle J. Hauske, Jonathan Emberson, David Preiss, Martin J. Landray, Colin Baigent, Christoph Wanner, Richard Haynes and William G. Herrington; on behalf of the EMPA-KIDNEY Collaborative Group |
Search Result 1